Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.

ABSTRACT:

Background

Programmed cell death protein 1(PD-1) blocking antibodies have been used to enhance immunity in solid tumors and achieve durable clinical responses with an acceptable safety profile in multiple types of cancer. However, only a subset of patients could benefit from PD-1 blockade therapy. Prognostic information including PD-1 ligand (PD-L1) expression, IFN-γ expression signature, tumor mutational burden, and microsatellite instability (MSI) have been evaluated for patients who are selected to receive immune checkpoint therapeutic treatment. Yet the relationship of those biomarkers in determining immune checkpoint therapy is largely unknown.

Methods

Immune-profiles of MSI subtype colon cancer were identified from integrating published MSI associated gene expression d

SUBMITTER: Wang H 

PROVIDER: S-EPMC6585086 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature